

STN SEARCH TRANSCRIPT

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sseptal623zct

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/Caplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/Caplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/Caplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/Caplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPCs For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:35:50 ON 02 NOV 2006

=> FILE REG)
'REGI' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can

specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> FILE REG
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 0.21
TOTAL SESSION 0.21

FILE 'REGISTRY' ENTERED AT 11:36:10 ON 02 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 NOV 2006 HIGHEST RN 912260-33-4
DICTIONARY FILE UPDATES: 1 NOV 2006 HIGHEST RN 912260-33-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\AKT INHs.str



chain nodes :
23


ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 24
25 26 27 32
chain bonds :
5-11 6-12 23-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 11-13 11-17 12-18 12-22
13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22 24-25 24-32 25-26 26-27
27-32
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 5-11 6-12 7-8 8-9 9-10 23-24 24-25
24-32 25-26 26-27 27-32
normalized bonds :
11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 11 : 12 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
32:Atom

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 11:36:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5546 TO ITERATE

36.1% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 106455 TO 115385
PROJECTED ANSWERS: 2 TO 251

L2 2 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 11:36:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 112035 TO ITERATE

100.0% PROCESSED 112035 ITERATIONS 633 ANSWERS
SEARCH TIME: 00.00.01

L3 633 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 166.94
TOTAL SESSION 167.15

FILE 'CAPLUS' ENTERED AT 11:36:48 ON 02 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Nov 2006 VOL 145 ISS 19
FILE LAST UPDATED: 1 Nov 2006 (20061101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3
L4 10 L3

=> D 1-5

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:608573 CAPLUS
DN 145:103647
TI Preparation of naphthyridine derivatives as inhibitors of Akt activity
IN Arruda, Jeannie M.; Campbell, Brian T.; Cosford, Nicholas D. P.; Hoffman, Jacob M.; Hu, Essa H.; Layton, Mark E.; Li, Yiwei; Liang, Jun; Rodzink,

Kevin J.; Siu, Tony; Stearns, Brian A.; Tehrani, Lida R.

Merck & Co., Inc., USA

PCT Int. Appl., 91 pp.

CODEN: PIXXD2

Patent

English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065601	A2	20060622	WO 2005-US44294	20051208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-636203P P 20041215

OS MARPAT 145:103647

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318893 CAPLUS

DN 144:370118

TI Preparation of pyrido[2,3-d]pyrimidine derivatives as inhibitors of Akt activity for treatment of cancer

IN Bilodeau, Mark T.; Cosford, Nicholas D. P.; Hartnett, John C.; Liang, Jun; Manley, Peter J.; Neilson, Lou Anne; Siu, Tony; Wu, Zhicai; Li, Yiwei

Merck & Co., Inc., USA

PCT Int. Appl., 102 pp.

CODEN: PIXXD2

Patent

English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006036395	A2	20060406	WO 2005-US29941	20050819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-603728P P 20040823

OS MARPAT 144:370118

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:86368 CAPLUS

DN 142:211437

TI Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors

AU Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.; Lindsley, Craig W.

Department of Medicinal Chemistry, Technology Enabled Synthesis Group,

Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA

Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 905-909

CODEN: BMCLE8; ISSN: 0960-894X

Elsevier B.V.

Journal

English

CASREACT 142:211437

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:74699 CAPLUS

DN 142:211435

TI Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

AU Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.

Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA

Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 761-764

CODEN: BMCLE8; ISSN: 0960-894X

Elsevier B.V.

Journal

English

CASREACT 142:211435

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:433750 CAPLUS

DN 141:7131

TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer

IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.

USA

U.S. Pat. Appl. Publ., 121 pp., which

CODEN: USXXCO

Patent

English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI US 2002-422312P	P	20021030		
US 2003-460911P	P	20030407		
OS MARPAT 141:7131				

>> D 5-10 IBIB ABS HITSTR

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:433750 CAPLUS

DOCUMENT NUMBER: 141:7131

TITLE: Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer

INVENTOR(S): Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.

USA

U.S. Pat. Appl. Publ., 121 pp., which

SOURCE:

NO PRIOR ART FOUND EXCEPT
VENUGAPALAN et al - LAST FEW PAGES
Q = ARYL.

CODEN: USXXCO

Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102360	A1	20040527	US 2003-678565	20031003
PRIORITY APPLN. INFO.:			US 2002-422312P	P 20021030
			US 2003-460911P	P 20030407

OTHER SOURCE(S): MARPAT 141:7131

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors I [wherein Q = (un)substituted heterocyclyl, aryl; U, V, W, and X = independently CH, N; Y, Z = independently CH, N, provided that at least one of Y and Z = N; n = 0-3; p = 0-2; q = 0-4; R1, R2, R7 = independently halo, CN, OH, CHO, NO2, or (un)substituted (cyclo)alkyl(oxy), alkenyl(oxy), alkynyl(oxy), heterocyclyl(oxy), acyl, carboxy, carbamoyl(oxy), ureido, sulfamoyl, etc.; R3, R4 = independently H, (perfluoro)alkyl; or CR3R4 = cycloalkyl, heterocyclyl; and pharmaceutically acceptable salts or stereoisomers thereof] or a combination of I and a protein kinase inhibitor II [wherein G = H2, O; X = C, N, SOO-2, O; m = 0-2; n = 0-2; p = 0-6; q = 0-4; R1 = independently H, halo, or (un)substituted (cyclo)alkyl, heterocyclyl, aryl, carbamoyl, amino, acyl, sulfamoyl, carboxy, etc.; R2 = H or (un)substituted (cyclo)alkyl(oxy), amino, aryloxy, heterocyclyloxy, alkenyloxy, alkynyloxy, etc.; R5 = independently H, halo, NO2, CN, or (un)substituted alkyl, alkenyl, alkynyl, carboxy, acyl, sulfamoyl, carbamoyl, ureido, amino, etc.; and pharmaceutically acceptable salts or stereoisomers thereof], optionally in combination with a third compound. Examples include syntheses for I and II and assays demonstrating Akt inhibitor activity, antitumor activity, and the synergistic effect of combinations of AKT inhibitors and/or protein kinase inhibitors on caspase 3 activity. For instance, III=HCl was prepared in an 8-step reaction sequence culminating with the cycloaddn. of 4-(2-aminoprop-2-yl)benzil and o-phenylenediamine using glacial acetic acid in H2O, followed by work up with chloroform and ethanolic HCl. III=HCl, a selective Akt1 and Akt2 inhibitor, demonstrated a 3.2-fold increase in caspase 3 activation over control compared to a 1.2-fold increase for a protein kinase inhibitor. Combination treatment produced a 9-fold increase in caspase 3 activation.

612847-29-7P 612848-47-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)

612847-29-7 CAPLUS

6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612848-47-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinolaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-46-1


CMF C34 H29 N9 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 612847-27-5P 612847-28-6P 612847-30-0P
612847-32-2P 612847-33-3P 612847-34-4P
612847-35-5P 612847-36-6P 612847-37-7P
612847-38-8P 612847-40-2P 612847-41-3P
612847-42-4P 612847-43-5P 612847-45-7P
612847-47-9P 612847-49-1P 612847-51-5P
612847-52-6P 612847-53-7P 612847-55-9P
612847-57-1P 612847-59-3P 612847-61-7P
612847-62-8P 612847-63-9P 612847-65-1P
612847-67-3P 612847-65-5P 612847-69-9P
612847-91-3P 612847-93-5P 612847-95-7P
612847-97-9P 612847-99-1P 612848-01-8P
612848-03-0P 612848-05-2P 612848-07-4P
612848-09-6P 612848-11-0P 612848-13-2P
612848-15-4P 612848-17-6P 612848-19-8P
612848-20-1P 612848-21-2P 612848-23-4P
612848-24-5P 612848-25-6P 612848-26-7P
612848-27-8P 612848-29-0P 612848-31-4P
612848-32-5P 612848-33-6P 612848-35-8P
612848-37-0P 612848-39-2P 612848-41-6P
612848-43-8P 612848-44-9P 612848-46-1P
612848-48-3P 612848-49-4P 612848-50-7P


612848-51-8P 612848-53-0P 612848-56-3P
612848-57-4P 612848-59-6P 612848-61-0P
612848-63-2P 612848-65-4P 616870-54-3P
695816-06-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors
and indoles as protein kinase inhibitors for use in synergistic
combination therapy for treatment of cancer)

RN 612847-27-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-
quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-28-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-
quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA
INDEX NAME)


CM 1

CRN 612847-27-5
CMP C33 H29 N5 O



CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 612847-30-0 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-
1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA
INDEX NAME)

CM 1


CRN 612847-29-7
CMP C34 H29 N5 O3



PAGE 1-A



PAGE 1-B




RN 612847-34-4 CAPLUS


CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-
yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 612847-33-3
CMP C40 H38 N8 O2



PAGE 1-A





PAGE 1-B




CM 2

CRN 76-05-1
CMP C2 H F3 O2



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-32-2 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-
1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA
INDEX NAME)


CM 1

CRN 612847-31-1
CMP C34 H29 N5 O3



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-33-3 CAPLUS

CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-
yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl-,
(9CI) (CA INDEX NAME)

RN 612847-35-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-
2-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-36-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-
2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX
NAME)


CM 1

CRN 612847-35-5
CMP C32 H28 N6 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 612847-37-7 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(2-phenylpyrido[3,4-b]pyrazin-
3-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-38-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(2-phenylpyrido[3,4-b]pyrazin-
3-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX
NAME)

NAME)


CM 1

CRN 612847-37-7
CMF C32 H28 N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-40-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612847-41-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-40-2
CMF C34 H29 N9 O




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612847-42-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612847-43-5 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612847-45-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[1-[[4-(6,7-diamino-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-44-6
CMF C33 H31 N7 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612847-47-9 CAPLUS
CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-46-8
CMF C33 H28 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612847-49-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[1-[[4-[[3-(2-aminophenyl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-48-0
CMF C33 H30 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-51-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-[[3-phenyl-2-quinoxaliny]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-50-4
CMF C32 H26 Cl2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-52-6 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-53-7 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-52-6
CMF C33 H27 N5 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-59-3 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-58-2
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-61-7 CAPLUS
CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-60-6
CMF C32 H26 F2 N4 O


Absolute stereochemistry.

RN 612847-55-9 CAPLUS
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-54-8
CMF C33 H27 F3 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-57-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-56-0
CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-62-8 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-63-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-62-8
CMF C29 H25 N5 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-65-1 CAPLUS
CN 4-Thiazolecarboxamide, N-((3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-64-0
CMP C29 H25 N5 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-67-3 CAPLUS
CN 4-Thiazolidinecarboxamide, N-((3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-66-2
CMP C29 H29 N5 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-85-5 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-84-4
CMP C29 H26 N6 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMP C2 H F3 O2




RN 612847-89-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-((3R)-3-((5-thiazolylcarbonyl)amino)-1-pyrrolidinyl)methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-88-8
CMP C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-91-3 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-90-2
CMP C28 H24 N6 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-93-5 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-92-4
CMP C28 H24 N6 O S

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-95-7 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-94-6
CMP C28 H24 N6 O 8

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-97-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612847-96-8
CMP C29 H25 N5 O2 8

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612847-99-1 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-98-0
CMP C32 H29 N5 O



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-01-8 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-00-7
CMP C32 H29 N5 O2



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-03-0 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-02-9
CMP C32 H29 N5 O2



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612848-05-2 CAPLUS
CN Benzoic acid, 3-[[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-azetidiny]amino]carbonyl]amino]-, methyl ester, trifluoroacetate (9CI)

(CA INDEX NAME)


CM 1

CRN 612848-04-1
CMP C33 H29 N5 O3



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-07-4 CAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-06-3
CMP C32 H27 F2 N5 O2



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-09-6 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 612848-08-5
CMF C34 H31 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-11-0 CAPLUS
CN Acetamide, N-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-10-9
CMF C37 H37 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-13-2 CAPLUS
CN Acetamide, N-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-12-1
CMF C37 H37 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-15-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-14-3
CMF C31 H28 N8



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-17-6 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-16-5
CMF C31 H29 N9



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-19-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-18-7
CMF C31 H27 Cl N8




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-20-1 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 612848-21-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612848-20-1
CMF C31 H29 N9



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612848-23-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-chloro-3-phenyl-2-quinoxaliny)phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-22-3
CMF C31 H27 Cl N8




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-24-5 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612848-25-6 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-29-0 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-28-9
CMF C30 H27 N9



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-31-4 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-30-3
CMF C31 H28 N8 O

CRN 612848-24-5
CMF C30 H27 N9




CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 612848-26-7 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-27-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-26-7
CMF C30 H27 N9




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-32-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612848-33-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-32-5
CMF C32 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-35-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-34-7
CMF C32 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-37-0 CAPLUS
CN Quinoxaline, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-36-9
CMF C32 H28 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-39-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-38-1
CMF C32 H29 N7



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-41-6 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-40-5
CMF C32 H29 N7



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-43-8 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-42-7
CMF C31 H27 N7




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 612848-44-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinoliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-46-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612848-48-3 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-49-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-48-3
CMF C32 H28 N12




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-50-7 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-51-8 CAPLUS
CN 9H-Purin-6-amine, 9-[[4-[[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-50-7
CMF C32 H28 N12



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-53-0 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-7-[[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-52-9
CMF C31 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-56-3 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-43-5
CMF C40 H43 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-57-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-42-4
CMF C40 H43 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-59-6 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[2-[[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinioxaliny]]carbonyl]amino]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-58-5
CMF C40 H40 N6 O7

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-61-0 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinioxaliny]]carbonyl]amino]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-60-9
CMF C40 H40 N6 O7

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-63-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-62-1
CMF C41 H42 N6 O7

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-65-4 CAPLUS


CN 2H-Benzimidazol-2-one, 1-[1-[[4-[7-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-64-3
CMF C41 H42 N6 O7

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616870-54-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[[[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidiny]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-86-6
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 695816-06-9 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-methyl-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 695816-05-8
CMF C41 H45 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



IT 612847-31-1P 616868-61-2P 616868-62-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinoxalines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)


RN 612847-31-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, (9CI) (CA INDEX NAME)



RN 616868-61-2 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-76-7
CMF C34 H28 N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 616868-62-3 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-75-6
CMF C34 H28 N6 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:836856 CAPLUS
DOCUMENT NUMBER: 139:337991
TITLE: Preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity
INVENTOR(S): Lindsley, Craig W.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086403	A1	20031023	WO 2003-US10341	20030404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480880	AA	20031023	CA 2003-2480880	20030404
AU 2003230802	A1	20031027	AU 2003-230802	20030404
EP 1496906	A1	20050119	EP 2003-723899	20030404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005130977	A1	20050616	US 2003-510067	20030404
JP 2005530726	T2	20051013	JP 2003-583422	20030404
PRIORITY APPLN. INFO.: US 2002-370846P P 20020408			WO 2003-US10341 W 20030404	
OTHER SOURCE(S): MARPAT 139:337991				
GI				



AB The title compds. comprising a 2,3-diphenylquinoxaline moiety [I; u, v, w and x = CH, N; y, z = CH, N (provided that at least one of y and z = N); R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl, or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5 = H, aryl, heterocyclyl, etc.; R6 = (un)substituted NH2, alkyl, perfluoroalkyl, etc.; n = 0-3; p = 0-2; t = 2-6; m = 0-2] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared E.g., a 3-step synthesis of N-[4-(3-phenylquinoxalin-2-yl)benzyl] propanesulfonamide (starting from 4-bromomethylbenzil and 1,2-diaminobenzene), was given. The exemplified compds. I were found to have IC50 of ≤ 50 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.

IT 616224-52-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity for treating cancer)
RN 616224-52-3 CAPLUS
CN 1H-Indole-1,3(2H)-dione, 2-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-(9CI) (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:836848 CAPLUS
DOCUMENT NUMBER: 139:350754
TITLE: Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer
INVENTOR(S): Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.; Manley, Peter J.; Wu, Zhicai; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086394	A1	20031023	WO 2003-US10442	20030404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480800	AA	20031023	CA 2003-2480800	20030404
AU 2003223467	A1	20031027	AU 2003-223467	20030404
EP 1496896	A1	20050119	EP 2003-719597	20030404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533010	T2	20051104	JP 2003-583413	20030404
US 2005222155	A1	20051006	US 2004-510069	20041004
PRIORITY APPLN. INFO.: US 2002-370847P P 20020408			WO 2003-US10442 W 20030404	
OTHER SOURCE(S): MARPAT 139:350754				
GI				




AB The title compds. comprising a 2,3-diphenylquinoxaline moiety [I; u, v, w and x = CH, N; y, z = CH, N (provided that at least one of y and z = N);

= NR5R6, (un)substituted aryl, heterocyclyl; R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl, or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5, R6 = H, aryl, heterocyclyl, etc.; or NR5R6 = monocyclic or bicyclic heterocycle; R7 = halo, CN, CO2H, etc.; n = 0-3; p = 0-2; t = 2-6; m = 0-2; q = 0-4; r = 0-1] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared E.g., a 2-step synthesis of the quinoxaline II [starting from 4-bromomethylbenzil and 4-(2-keto-1-benzimidazol-1-yl)piperidine], was given. The exemplified compds. I were found to have IC50 of ≤ 50 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.


IT 612847-29-7P 612847-31-1P 612848-75-6P
612848-76-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2,3-diphenylquinoxaline derivate as inhibitors of Akt activity for treating cancer)
RN 612847-29-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612847-31-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612848-75-6 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612848-76-7 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


RN 612847-27-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



CRN 612847-27-5
CMP C33 H29 N5 O




CRN 76-05-1
CMF C2 H P3 Q2



CRN 612847-29-7
CMP C34 H29 N5 O3




CRN 76-05-1
CMF C2 H F3 Q2




CRN 612847-31-1
CMF C34 H29 N5 O3



CRN 76-05-1
CMF C2 H F3 02





PAGE 1-A




CRN 612847-33-3
CMP C40 H38 N8 O2


PAGE 1-A



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-35-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-36-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-35-5
CMF C32 H28 N6 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-37-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(2-phenylpyrido[3,4-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-38-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(2-phenylpyrido[3,4-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-37-7
CMF C32 H28 N6 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-40-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 612847-41-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-40-2
CMF C34 H29 N9 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-42-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 612847-43-5 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612847-44-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-(6,7-diamino-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 612847-45-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-(6,7-diamino-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-44-6
CMF C33 H31 N7 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-46-8 CAPLUS
CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612847-47-9 CAPLUS
CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-46-8
CMF C33 H28 N4




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-48-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[3-(2-aminophenyl)-2-quinoxaliny]phenyl]methyl]-4-piperidiny]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 612847-49-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[3-(2-aminophenyl)-2-quinoxaliny]phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-48-0
CMP C33 H30 N6 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 612847-50-4 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-51-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-50-4
CMP C32 H26 Cl2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 612847-52-6 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-53-7 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-52-6
CMP C33 H27 N5 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 612847-54-8 CAPLUS
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-55-9 CAPLUS
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidiny]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-54-8
CMP C33 H27 F3 N4 O

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-56-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-57-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-56-0
CMP C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-58-2 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-59-3 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-58-2
CMP C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-60-6 CAPLUS
CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-61-7 CAPLUS
CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-60-6
CMP C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-62-8 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-63-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-62-8
CMP C29 H25 N5 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612847-64-0 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-65-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-64-0
CMF C29 H25 N5 O 5

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612847-66-2 CAPLUS
CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-67-3 CAPLUS
CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-66-2
CMF C29 H29 N5 O 5

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612847-84-4 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612847-85-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-84-4
CMF C29 H26 N6 O 5

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-86-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-88-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-89-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-88-8
CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-90-2 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-91-3 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-90-2
CMF C28 H24 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-92-4 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-93-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-92-4
CMF C28 H24 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-94-6 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-95-7 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-94-6
CMF C28 H24 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-96-8 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612847-97-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 612847-96-8
CMF C29 H25 N5 O2 S


Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612847-98-0 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612847-99-1 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-98-0
CMF C32 H29 N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-00-7 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]- (9CI) (CA INDEX NAME)




RN 612848-01-8 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-00-7
CMF C32 H29 N5 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-02-9 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]- (9CI) (CA INDEX NAME)




RN 612848-03-0 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-02-9
CMF C32 H29 N5 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-04-1 CAPLUS
CN Benzoic acid, 3-[[[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 612848-05-2 CAPLUS
CN Benzoic acid, 3-[[[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]amino]carbonyl]amino]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-04-1
CMF C33 H29 N5 O3



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612848-06-3 CAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyl]- (9CI) (CA INDEX NAME)




RN 612848-07-4 CAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[1-[[4-(3-phenyl-2-

quinoxaliny]phenyl)methyl]-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-06-3


CMF C32 H27 F2 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 612848-08-5 CAPLUS

CN 5-Quinoxalinol, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612848-09-6 CAPLUS

CN 5-Quinoxalinol, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-08-5

CMF C34 H31 N5 O



RN 612848-12-1 CAPLUS

CN Acetamide, N-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 612848-13-2 CAPLUS

CN Acetamide, N-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-12-1


CMF C37 H37 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 612848-14-3 CAPLUS


CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 612848-10-9 CAPLUS

CN Acetamide, N-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 612848-11-0 CAPLUS

CN Acetamide, N-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-10-9


CMF C37 H37 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 612848-15-4 CAPLUS

CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-14-3


CMF C31 H28 N8



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 612848-16-5 CAPLUS


CN 6-Quinoxalinamine, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612848-17-6 CAPLUS

CN 6-Quinoxalinamine, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-16-5
CMF C31 H29 N9



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-18-7 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-chloro-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-19-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-chloro-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-18-7
CMF C31 H27 Cl N8



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-20-1 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-21-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-20-1
CMF C31 H29 N9



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-22-3 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-chloro-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-23-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-chloro-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-22-3
CMF C31 H27 Cl N8



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-24-5 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-25-6 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-24-5
CMF C30 H27 N9



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-26-7 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-27-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-26-7
CMF C30 H27 N9



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-28-9 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 612848-29-0 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-28-9
CMP C30 H27 N9



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-30-3 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612848-31-4 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 612848-30-3
CMP C31 H28 N8 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-32-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612848-33-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-32-5
CMP C32 H28 N8 O2



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-34-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612848-35-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-34-7
CMP C32 H28 N8 O2



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-36-9 CAPLUS
CN Quinoxaline, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612848-37-0 CAPLUS
CN Quinoxaline, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-36-9
CMP C32 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-38-1 CAPLUS
CN 6-Quinoxalinamine, 2-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612848-39-2 CAPLUS
CN 6-Quinoxalinamine, 2-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-38-1
CMF C32 H29 N7




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-40-5 CAPLUS
CN 6-Quinoxalinamine, 3-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 612848-41-6 CAPLUS
CN 6-Quinoxalinamine, 3-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-40-5
CMF C32 H29 N7




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-42-7 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612848-43-8 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[[4-[(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-42-7
CMF C31 H27 N7




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-44-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-45-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-44-9
CMF C34 H30 N4 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-46-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-47-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[(3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-46-1
CMF C34 H29 N9 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-48-3 CAPLUS
CN 9H-Purin-6-amine, 9-[[4-[(3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-49-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-48-3
CMF C32 H28 N12




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-50-7 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 612848-51-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-50-7
CMF C32 H28 N12




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-52-9 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-7-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 612848-54-1 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-6-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 612848-55-2 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-6-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-54-1
CMF C31 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-56-3 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-43-5
CMF C40 H43 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-57-4 CAPLUS

CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-42-4
CMF C40 H43 N7 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-58-5 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoliny]carbonyl]amino]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-A

PAGE 1-B




RN 612848-59-6 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[[4-[[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]carbonyl]amino]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)
CM 1
CRN 612848-58-5
CMF C40 H40 N6 O7

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612848-60-9 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[[4-[[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]carbonyl]amino]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)



Absolute stereochemistry.

CMF C2 H F3 O2



RN 612848-62-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612848-63-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 612848-62-1
CMF C41 H42 N6 O7

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 612848-61-0 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[[4-[[4-[[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]carbonyl]amino]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 612848-60-9
CMF C40 H40 N6 O7

Absolute stereochemistry.




CM 2
CRN 76-05-1


PAGE 1-A



PAGE 1-B





CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 612848-64-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[[7-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 612848-65-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[7-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxalinyloxy]phenylmethyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-64-3
CMF C41 H42 N6 O7

Absolute stereochemistry.




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 616867-65-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[2-phenyl-3-quinolinyloxy]phenylmethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616867-66-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinoxalinyloxy]phenylmethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)





RN 616867-67-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[7-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinoxalinyloxy]phenylmethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616867-68-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-1,8-naphthyridin-2-yl]phenylmethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616867-69-7 CAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-1,8-naphthyridin-2-yl]phenylmethyl]-4-piperidinyl]-, 4-oxide (9CI) (CA INDEX NAME)



RN 616867-70-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[2,4-diamino-6-phenylpyrido[2,3-d]pyrimidin-7-yl]phenylmethyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616867-71-1 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[[4-[[3-phenyl-2-quinoxalinyloxy]phenylmethyl]-3-piperidinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)



RN 616867-72-2 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[[4-[[3-phenyl-2-quinoxalinyloxy]phenylmethyl]-3-piperidinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616867-71-1
CMF C32 H29 N3 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616867-73-3 CAPLUS
CN Urea, N-(1-methylethyl)-N'-[[1-[[4-[[3-phenyl-2-quinoxalinyloxy]phenylmethyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-74-4 CAPLUS
CN Urea, N-(1-methylethyl)-N'-[[1-[[4-[[3-phenyl-2-quinoxalinyloxy]phenylmethyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616867-73-3
CMF C31 H35 N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616867-75-5 CAPLUS
CN Urea, N-(3-fluorophenyl)-N'-[[1-[[4-[[3-phenyl-2-quinoxalinyloxy]phenylmethyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-76-6 CAPLUS
CN Urea, N-(3-fluorophenyl)-N'-{[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl}-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616867-75-5
CMP C34 H32 F N5 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 616867-77-7 CAPLUS
CN Urea, N-phenyl-N'-{[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl}- (9CI) (CA INDEX NAME)




RN 616867-78-8 CAPLUS
CN Urea, N-phenyl-N'-{[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl}-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616867-81-3 CAPLUS
CN Benzenesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-82-4 CAPLUS
CN Benzenesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616867-81-3
CMP C33 H32 N4 O2 S




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616867-83-5 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

CRN 616867-77-7
CMP C34 H33 N5 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616867-79-9 CAPLUS
CN Urea, N-[[4-bromophenyl]methyl]-N'-{[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl}- (9CI) (CA INDEX NAME)



RN 616867-80-2 CAPLUS
CN Urea, N-[[4-bromophenyl]methyl]-N'-{[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl}-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616867-79-9
CMP C35 H34 Br N5 O



RN 616867-84-6 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616867-83-5
CMP C33 H31 Br N4 O2 S




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 616867-85-7 CAPLUS
CN Benzenemethanesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 616867-86-8 CAPLUS
CN Benzenemethanesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI)

(CA INDEX NAME)

CM 1

CRN 616867-85-7


CMP C34 H34 N4 O2 S



CM 2


CRN 76-05-1

CMP C2 H F3 O2



RN 616867-87-9 CAPLUS

CN Benzenesulfonamide, 3,4-dimethoxy-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 616867-88-0 CAPLUS

CN Benzenesulfonamide, 2,2,2-trifluoro-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616867-87-9

CMP C35 H36 N4 O4 S



RN 616867-91-5 CAPLUS

CN Ethanesulfonamide, 2,2,2-trifluoro-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 616867-92-6 CAPLUS

CN Ethanesulfonamide, 2,2,2-trifluoro-N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-91-5


CMP C29 H29 F3 N4 O2 S



CM 2


CRN 76-05-1

CMP C2 H F3 O2



RN 616867-93-7 CAPLUS


CN 7-Quinolinesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



CM 2


CRN 76-05-1

CMP C2 H F3 O2



RN 616867-89-1 CAPLUS

CN 2-Thiophenesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 616867-90-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-89-1


CMP C31 H30 N4 O2 S2



CM 2

CRN 76-05-1

CMP C2 H F3 O2




RN 616867-94-8 CAPLUS

CN 7-Quinolinesulfonamide, N-[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-93-7


CMP C36 H33 N5 O2 S



CM 2


CRN 76-05-1

CMP C2 H F3 O2



RN 616867-95-9 CAPLUS

CN 2(1H)-Quinazolinone, 3,4-dihydro-3-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616867-96-0 CAPLUS

CN 2(1H)-Quinazolinone, 3,4-dihydro-3-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616867-95-9


CMP C34 H31 N5 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616867-97-1 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-4-phenyl-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 616867-98-2 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-4-phenyl-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-97-1
CMP C35 H31 N5 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-00-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-2-pyrrolidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-99-3
CMP C27 H24 N6 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-04-3 CAPLUS
CN Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-03-2
CMP C32 H25 F5 N4 O2 S




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-06-5 CAPLUS
CN Acetamide, N-[[4-[[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]amino]sulfonyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-05-4
CMP C34 H33 N5 O3 S




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-08-7 CAPLUS

CN Quinoxaline, 2-[[4-[[[3-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-3-phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-07-6
CMP C33 H29 N5




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-10-1 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-09-8
CMP C29 H31 Cl N4 O2 S




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 616868-12-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-11-2
CMF C32 H29 Cl N4 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616868-14-5 CAPLUS
CN 1-Butanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-13-4
CMF C30 H34 N4 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616868-16-7 CAPLUS
CN Methanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-15-6
CMF C27 H28 N4 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616868-18-9 CAPLUS
CN Ethanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-17-8
CMF C28 H30 N4 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-19-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-methyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616868-20-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-methyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-19-0
CMF C34 H31 N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-21-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-methyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616868-22-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-methyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-21-4
CMF C34 H31 N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-23-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616868-24-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616868-23-6
CMF C33 H28 Cl N5 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-25-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616868-26-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-25-8
CMP C33 H28 Cl N5 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-27-0 CAPLUS
CN Acetamide, N-[2-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]ethyl]- (9CI) (CA INDEX NAME)




RN 616868-28-1 CAPLUS
CN Acetamide, N-[2-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-27-0
CMP C37 H36 N6 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-30-5 CAPLUS
CN Acetamide, N-[2-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-29-2
CMP C37 H36 N6 O2



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-31-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-(methylsulfonyl)-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-32-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-(methylsulfonyl)-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-31-6
CMP C34 H31 N5 O3 S



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-33-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-(methylsulfonyl)-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-34-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-(methylsulfonyl)-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-33-8
CMP C34 H31 N5 O3 S



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-35-0 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 616868-36-1 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-35-0
CMF C35 H34 N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-37-2 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616868-38-3 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-37-2
CMF C35 H34 N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-39-4 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616868-40-7 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-39-4
CMF C33 H30 N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-41-8 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616868-42-9 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-41-8
CMF C33 H30 N6 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 616868-43-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-

yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 616868-44-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-43-0
CMF C40 H38 N8 O2

PAGE 1-A




PAGE 1-B




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-45-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 616868-46-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-45-2
CMF C36 H33 N5 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-47-4 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 616868-48-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-47-4
CMF C36 H33 N5 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-49-6 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 616868-50-9 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-49-6
CMF C36 H34 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-51-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 616868-52-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-51-0
CMF C36 H34 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-53-2 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxy-2-phenylethyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 616868-54-3 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxy-2-phenylethyl)-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-53-2
CMF C42 H38 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-55-4 CAPLUS

CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxy-2-phenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 616868-56-5 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxy-2-phenylethyl)-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 616868-55-4
CMF C42 H38 N6 O3



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-57-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-fluoro-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616868-58-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-fluoro-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate

(9CI) (CA INDEX NAME)


CM 1
CRN 616868-57-6
CMF C33 H28 F N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-59-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-fluoro-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616868-60-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-fluoro-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-59-8
CMF C33 H28 F N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-61-2 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-76-7
CMF C34 H28 N6 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-62-3 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612848-75-6
CMF C34 H28 N6 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-63-4 CAPLUS
CN Piperazine, 1-[[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 616868-64-5 CAPLUS
CN Piperazine, 1-[[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]carbonyl]-4-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-63-4
CMF C39 H39 N7 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-65-6 CAPLUS
CN Piperazine, 1-[[3-[[4-[[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 616868-66-7 CAPLUS
CN Piperazine, 1-[[3-[[4-[[2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]carbonyl]-4-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-65-6
CMF C39 H39 N7 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616868-67-8 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(5-hydroxypentyl)-2-phenyl- (9CI) (CA INDEX NAME)


yl)-1-piperidinyl]methyl]phenyl]-N-(5-hydroxypentyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 616868-68-9 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(5-hydroxypentyl)-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-67-8
CMF C39 H40 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616868-69-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(5-hydroxypentyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 616868-70-3 CAPLUS

CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(5-hydroxypentyl)-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-69-0
CMF C39 H40 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616868-71-4 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]-3-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 616868-72-5 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-71-4
CMF C41 H45 N7 O2




PAGE 1-A

PAGE 1-B




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616868-73-6 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 616868-74-7 CAPLUS
 CN 6-Quinoxalinecarboxamide, 3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(3-(dimethylamino)-2,2-dimethylpropyl)-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-73-6
 CMP C41 H45 N7 O2





CM 2

CRN 76-05-1
 CMP C2 H F3 O2



RN 616868-75-8 CAPLUS
 CN 6-Quinoxalinecarboxamide, 2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(3-hydroxy-2,2-dimethylpropyl)-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)





RN 616868-76-9 CAPLUS

CN 6-Quinoxalinecarboxamide, 2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(3-hydroxy-2,2-dimethylpropyl)-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616868-75-8
 CMP C39 H40 N6 O3





CM 2

CRN 76-05-1
 CMP C2 H F3 O2






RN 616868-77-0 CAPLUS
 CN 6-Quinoxalinecarboxamide, 3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(3-hydroxy-2,2-dimethylpropyl)-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616868-78-1 CAPLUS
 CN 6-Quinoxalinecarboxamide, 3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-(3-hydroxy-2,2-dimethylpropyl)-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616868-77-0
 CMP C39 H40 N6 O3




RN 616868-80-5 CAPLUS

CN 6-Quinoxalinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616868-79-2
 CMP C41 H37 N7 O4 S


PAGE 1-A



PAGE 1-B




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-81-6 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 616868-82-7 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-81-6
CMP C41 H37 N7 O4 S


PAGE 1-A



PAGE 1-B




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-84-9 CAPLUS
CN Methanesulfonamide, N-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-83-8
CMP C34 H32 N6 O3 S




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-86-1 CAPLUS
CN Methanesulfonamide, N-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-85-0
CMP C34 H32 N6 O3 S



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-87-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(6-methoxy-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-88-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(6-methoxy-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-87-2
CMP C34 H31 N5 O2



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616868-89-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(7-methoxy-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-90-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(7-methoxy-3-phenyl-2-quinoxaliny]phenyl)methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-89-4
CMP C34 H31 N5 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2





RN 616868-91-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[6-[[4-aminophenyl)sulfonyl]-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616868-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[6-[[4-aminophenyl)sulfonyl]-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-91-8
CMF C39 H34 N6 O3 S




IT 616868-95-2P 616868-96-3P 616868-97-4P
616868-98-5P 616868-99-6P 616869-00-2P
616869-01-3P 616869-02-4P 616869-03-5P
616869-04-6P 616869-05-7P 616869-06-8P
616869-07-9P 616869-08-0P 616869-09-1P
616869-10-4P 616869-11-5P 616869-12-6P
616869-13-7P 616869-14-8P 616869-15-9P
616869-16-0P 616869-17-1P 616869-18-2P
616869-19-3P 616869-20-6P 616869-21-7P
616869-22-8P 616869-23-9P 616869-24-0P
616869-25-1P 616869-26-2P 616869-27-3P
616869-28-4P 616869-29-5P 616869-30-8P
616869-31-9P 616869-32-0P 616869-33-1P
616869-34-2P 616869-35-3P 616869-36-4P
616869-37-5P 616869-38-6P 616869-39-7P
616869-40-0P 616869-41-1P 616869-42-2P
616869-43-3P 616869-44-4P 616869-45-5P
616869-46-6P 616869-47-7P 616869-48-8P
616869-49-9P 616869-50-2P 616869-51-3P
616869-52-4P 616869-53-5P 616869-54-6P
616869-55-7P 616869-56-8P 616869-58-0P
616869-60-4P 616869-62-6P 616869-68-2P
616869-70-6P 616869-71-7P 616869-72-8P
616869-73-9P 616869-74-0P 616869-75-1P
616869-76-2P 616869-77-3P 616869-78-4P
616869-81-9P 616869-82-0P 616869-83-1P
616869-84-2P 616869-85-3P 616869-86-4P
616869-87-5P 616869-88-6P 616869-89-7P
616869-90-0P 616869-91-1P 616869-92-2P
616869-93-3P 616869-94-4P 616869-95-5P
616869-96-6P 616869-97-7P 616869-98-8P
616869-99-9P 616870-00-9P 616870-01-0P
616870-02-1P 616870-03-2P 616870-05-4P
616870-06-5P 616870-07-6P 616870-08-7P
616870-09-8P 616870-10-1P 616870-11-2P
616870-12-3P 616870-13-4P 616870-14-5P
616870-15-6P 616870-26-9P 616870-27-0P
616870-28-1P 616870-29-2P 616870-30-5P
616870-31-6P 616870-32-7P 616870-33-8P
616870-34-9P 616870-35-0P 616870-36-1P
616870-37-2P 616870-40-7P 616870-42-9P
616870-53-2P 616870-54-3P 616870-57-6P
616870-58-7P 616870-59-8P 616870-60-1P
616870-61-2P 616870-62-3P 616870-63-4P
616870-64-5P 616870-65-6P 616870-66-7P
616870-67-8P 616870-68-9P 616870-69-0P
616870-70-3P 616870-71-4P 616870-72-5P
616870-73-6P 616870-74-7P 616870-75-8P
616870-76-9P 616870-77-0P 616870-78-1P
616870-79-2P 616870-80-5P 616870-81-6P
616870-82-7P 616870-83-8P 616870-84-9P
616870-85-0P 616870-86-1P 616870-87-2P
616870-88-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses)

(preparation of 2,3-diphenylquinoxaline derivate as inhibitors of Akt

CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-93-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[6-[[4-aminophenyl)sulfonyl]-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616868-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-[[6-[[4-aminophenyl)sulfonyl]-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-93-0
CMF C39 H34 N6 O3 S



CM 2
CRN 76-05-1
CMF C2 H F3 O2


activity for treating cancer)

RN 616868-95-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-nitro-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-96-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-nitro-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-95-2
CMF C33 H28 N6 O3



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-97-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-nitro-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616868-98-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-nitro-3-phenyl]-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616868-97-4
CMF C33 H28 N6 O3



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616868-99-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-benzoyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 616869-00-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-benzoyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616868-99-6
CMF C40 H33 N5 O2




2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616869-04-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-6-(trifluoromethyl)-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-03-5
CMF C34 H28 F3 N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-05-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-7-(trifluoromethyl)-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616869-06-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-7-(trifluoromethyl)-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-05-7

CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-01-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-benzoyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616869-02-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-benzoyl-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-01-3
CMF C40 H33 N5 O2




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-03-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-6-(trifluoromethyl)-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CMF C34 H28 F3 N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-07-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616869-08-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-07-9
CMF C33 H30 N6 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-09-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl)methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616869-10-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl)methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-09-1
CMF C33 H30 N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-11-5 CAPLUS
CN 6-Quinoxalinesulfonamide, 7-chloro-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-12-6 CAPLUS
CN 6-Quinoxalinesulfonamide, 7-chloro-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-11-5
CMF C33 H29 Cl N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-13-7 CAPLUS
CN 6-Quinoxalinesulfonamide, 7-chloro-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-14-8 CAPLUS
CN 6-Quinoxalinesulfonamide, 7-chloro-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-13-7
CMF C33 H29 Cl N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-15-9 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-7-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-16-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-7-methyl-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-15-9
CMF C35 H32 N6 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-17-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-7-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-18-2 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-7-methyl-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-17-1
CMF C35 H32 N6 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-19-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-chloro-6-fluoro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616869-20-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(7-chloro-6-fluoro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-19-3
CMP C33 H27 Cl F N5 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616869-21-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-chloro-7-fluoro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616869-22-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6-chloro-7-fluoro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-21-7
CMP C33 H27 Cl F N5 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616869-23-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6,7-dichloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 616869-24-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6,7-dichloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidiny]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-23-9
CMP C33 H27 Cl2 N5 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616869-25-1 CAPLUS
CN Methanesulfonamide, N-[2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-3-phenyl-6-quinoxaliny]- (9CI) (CA INDEX NAME)



RN 616869-26-2 CAPLUS
CN Methanesulfonamide, N-[2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-3-phenyl-6-quinoxaliny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616869-25-1
CMP C34 H32 N6 O2 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 616869-27-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-28-4 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-27-3
CMP C34 H29 N5 O2




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616869-29-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidiny]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-30-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-29-5
CMF C34 H29 N5 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616869-31-9 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-methyl-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 616869-32-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-methyl-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616869-31-9

CMF C35 H32 N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-33-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-methyl-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616869-34-2 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-methyl-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616869-33-1
CMF C35 H32 N6 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 616869-35-3 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-chloro-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616869-36-4 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-chloro-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-35-3
CMF C33 H29 Cl N6 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-37-5 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-chloro-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616869-38-6 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-chloro-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616869-37-5
CMF C33 H29 Cl N6 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-39-7 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-7-methyl-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)




RN 616869-40-0 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-7-methyl-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 616869-39-7
CMF C37 H36 N6 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-41-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-7-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 616869-42-2 CAPLUS
CN 6-Quinoxalinecarboxamide, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-N-(2-hydroxyethyl)-7-methyl-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 616869-41-1
CMF C37 H36 N6 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-43-3 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-methoxy-3-phenyl- (9CI) (CA INDEX NAME)




RN 616869-44-4 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-methoxy-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-43-3
CMF C34 H31 N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-45-5 CAPLUS
CN Quinoxaline, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-methoxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 616869-46-6 CAPLUS
CN Quinoxaline, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-methoxy-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-45-5
CMF C34 H31 N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-47-7 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




RN 616869-48-8 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-fluoro-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-47-7
CMF C33 H28 F N5



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-49-9 CAPLUS
CN Quinoxaline, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-fluoro-2-phenyl- (9CI) (CA INDEX NAME)




RN 616869-50-2 CAPLUS
CN Quinoxaline, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-fluoro-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616869-49-9
CMF C33 H28 F N5



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616869-51-3 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-52-4 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-51-3
CMF C34 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-53-5 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-54-6 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-53-5
CMF C34 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-55-7 CAPLUS
CN Acetamide, N-[2-[2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]ethyl]- (9CI) (CA INDEX NAME)



RN 616869-56-8 CAPLUS
CN Acetamide, N-[2-[2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-55-7
CMF C37 H36 N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616869-58-0 CAPLUS
CN Acetamide, N-[2-[3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-57-9
CMF C37 H36 N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616869-60-4 CAPLUS
CN Methanone, [2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-59-1
CMF C40 H33 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616869-62-6 CAPLUS
CN Methanone, [3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxaliny]phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-61-5
CMF C40 H33 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616869-68-2 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-67-1
CMF C35 H31 N5 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616869-70-6 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-69-3
CMF C35 H31 N5 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-71-7 CAPLUS
CN Pyrido[3,4-b]pyrazine, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-72-8 CAPLUS
CN Pyrido[3,4-b]pyrazine, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-71-7
CMF C32 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-73-9 CAPLUS
CN Pyrido[3,4-b]pyrazine, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-74-0 CAPLUS
CN Pyrido[3,4-b]pyrazine, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-73-9
CMF C32 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-75-1 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-76-2 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-75-1
CMF C32 H28 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616869-77-3 CAPLUS
CN Pyrido[2,3-b]pyrazine, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 616869-78-4 CAPLUS
CN Pyrido[2,3-b]pyrazine, 3-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-77-3
CMF C32 H28 N6




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 616869-81-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-[6-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616869-82-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[7-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616869-83-1 CAPLUS
CN Quinoxaline, 2-[[4-[[4-(1H-indol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-84-2 CAPLUS
CN Quinoxaline, 3-[[4-[[4-(1H-indol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-85-3 CAPLUS
CN Quinoxaline, 2-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(1-methyl-1H-tetrazol-5-yl)-3-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-86-4 CAPLUS
CN Quinoxaline, 2-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl]- (9CI) (CA INDEX NAME)





RN 616869-87-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-88-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-89-7 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[2-(diethylamino)ethyl]-3-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-90-0 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[2-(diethylamino)ethyl]-3-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-91-1 CAPLUS
CN 6-Quinoxalinecarboxamide, N-methyl-3-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-92-2 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[3-(1H-imidazol-1-yl)propyl]-3-[[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-B



RN 616869-93-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-94-4 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-95-5 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[[2-(diethylamino)ethyl]-3-[[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 616869-96-6 CAPLUS
CN Pyrido[2,3-b]pyrazine, 7-bromo-2-[[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-methyl-3-phenyl]- (9CI) (CA INDEX NAME)




RN 616869-97-7 CAPLUS
CN Pyrido[2,3-b]pyrazine, 7-bromo-3-[[4-[(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 616869-98-8 CAPLUS
CN Pyrido[2,3-b]pyrazine, 7-bromo-6-methyl-2-[[4-[(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616869-99-9 CAPLUS
CN Pyrido[2,3-b]pyrazine, 7-bromo-3-[[4-[(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 616870-00-9 CAPLUS
CN 1,8-Naphthyridine, 2-[[4-[(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 616870-01-0 CAPLUS
CN 1,8-Naphthyridine, 2-[[4-[(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 616870-05-4 CAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616870-04-3
CMP C35 H31 N9 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 616870-06-5 CAPLUS
CN 9H-Purin-6-amine, 9-[[1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 616870-07-6 CAPLUS
CN 9H-Purin-6-amine, 9-[[1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-

NAME)


CM 1

CRN 616870-00-9
CMP C34 H31 N5




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616870-02-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)



RN 616870-03-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616870-02-1
CMP C36 H32 N8 O



quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616870-06-5
CMP C34 H31 N11




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 616870-08-7 CAPLUS
CN 9H-Purin-6-amine, 9-[[1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)




RN 616870-09-8 CAPLUS
CN 9H-Purin-6-amine, 9-[[1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinolinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 616870-08-7
CMP C31 H28 N8



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616870-10-1 CAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-[[4-(3-phenyl-1,8-naphthyridin-2-yl)phenyl]methyl]-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 616870-11-2 CAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-[[4-(3-phenyl-1,8-naphthyridin-2-yl)phenyl]methyl]-4-piperidinyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616870-10-1
CMP C32 H28 N6 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616870-12-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-(4-amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl]methyl]-4-piperidinyl-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 616870-13-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[4-(4-amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl]methyl]-4-piperidinyl-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616870-12-3
CMP C32 H29 N7 O



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616870-14-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-2(1H)-one, 4-amino-7-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 616870-15-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-2(1H)-one, 4-amino-7-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 616870-14-5
CMP C32 H29 N7 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 616870-26-9 CAPLUS
CN Quinoxaline, 2-[[4-[(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 616870-27-0 CAPLUS
CN Quinoxaline, 2-[[4-[(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 616870-28-1 CAPLUS
CN Acetamide, N-[[2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]propyl]- (9CI) (CA INDEX NAME)




RN 616870-29-2 CAPLUS
CN 6-Quinoxalinesulfonamide, 2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 616870-30-5 CAPLUS
CN 6-Quinoxalinesulfonamide, 3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 616870-31-6 CAPLUS
CN Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-[[4-[(3-phenyl-2-quinoxaliny]phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616870-32-7 CAPLUS
CN Acetamide, N-[4-[[[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 616870-33-8 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616870-34-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616870-35-0 CAPLUS
CN 1-Butanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616870-36-1 CAPLUS
CN Methanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 616870-37-2 CAPLUS
CN Ethanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616870-40-7 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 616870-42-9 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 616870-53-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(2-phenyl-3-quinoliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-65-3
CMF C34 H30 N4 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-54-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[[[3R]-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-86-6
CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-57-6 CAPLUS
CN Quinoxaline, 2-phenyl-3-[4-[[4-(2-pyridinyl)-1-piperidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-26-9
CMF C31 H28 N4




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-58-7 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616870-27-0
CMF C33 H29 N5




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-59-8 CAPLUS
CN Acetamide, N-[2-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxaliny]propyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-28-1
CMF C38 H38 N6 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-60-1 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-33-3
CMF C40 H38 N8 O2


PAGE 1-A



PAGE 1-B




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-61-2 CAPLUS
CN Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-31-6
CMF C32 H25 F5 N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-62-3 CAPLUS
CN Acetamide, N-[4-[[[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-piperidinyl]amino]sulfonyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-32-7
CMF C34 H33 N5 O3 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-63-4 CAPLUS
CN 1-Propenesulfonamide, 3-chloro-N-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-33-8
CMF C29 H31 Cl N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-64-5 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-34-9
CMF C32 H29 Cl N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-65-6 CAPLUS
CN 1-Butanesulfonamide, N-[1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616870-35-0
CMF C30 H34 N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-66-7 CAPLUS
CN Methanesulfonamide, N-[[4-[(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-36-1
CMF C27 H28 N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-67-8 CAPLUS
CN Ethanesulfonamide, N-[[4-[(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-

piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-37-2
CMF C28 H30 N4 O2 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-68-9 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 3-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-40-7
CMF C36 H33 N5 O3




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-69-0 CAPLUS
CN 5-Quinoxalinecarboxylic acid, 2-[[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, ethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616870-42-9
CMF C36 H33 N5 O3




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-70-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-81-9
CMF C35 H31 N9 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-71-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-82-0
CMF C35 H31 N9 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-72-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-66-4
CMF C35 H31 N9 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-73-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[7-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-67-5
CMF C35 H31 N9 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-74-7 CAPLUS
CN Quinoxaline, 2-[4-[[4-(1H-indol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

NAME)
CM 1
CRN 616869-83-1
CMF C36 H32 N8




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-75-8 CAPLUS
CN Quinoxaline, 3-[4-[[4-(1H-indol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-84-2
CMF C36 H32 N8




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-76-9 CAPLUS

CN Quinoxaline, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-85-3
CMF C36 H33 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-77-0 CAPLUS
CN Quinoxaline, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-86-4
CMF C36 H33 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-78-1 CAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-[[4-(3-phenyl-1,8-naphthyridin-2-yl)phenyl]methyl]-4-piperidinyl]-, 4-oxide, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616867-69-7
CMF C32 H28 N6 O2




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 616870-79-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 616869-87-5
CMF C35 H31 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616870-80-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-88-6
CMF C35 H31 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616870-81-6 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-89-7
CMF C41 H45 N7 O




PAGE 1-A

CRN 616869-91-1
CMF C36 H34 N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616870-84-9 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-3-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-92-2
CMF C41 H40 N8 O



PAGE 1-A


PAGE 1-B



CM 2


CRN 76-05-1
CMF C2 H F3 O2

PAGE 1-B



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616870-82-7 CAPLUS
CN 6-Quinoxalinecarboxamide, N-(2-hydroxyethyl)-3-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 616869-90-0
CMF C37 H36 N6 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616870-83-8 CAPLUS
CN 6-Quinoxalinecarboxamide, N-methyl-3-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1



RN 616870-85-0 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-93-3
CMF C34 H28 F N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 616870-86-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616869-94-4
CMF C34 H28 F N5 O2




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 616870-87-2 CAPLUS
 CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)
 CM 1
 CRN 616869-95-5
 CMF C40 H42 F N7 O





PAGE 1-A



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 616870-88-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[1-[[4-(2,4-diamino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)
 CM 1
 CRN 616867-70-0
 CMF C32 H30 N8 O




AB Triazolo[4,3-b]pyridazines I [R1 = (un)substituted Ph, furyl, thienyl, pyridinyl; R2 = substituted NH2, OH; R3 = H, R4 = (un)substituted cycloalkyl, aryl; R3R4 = (un)substituted CH:CHCH:CH] and quinazolines II [R5, R6 = (un)substituted Ph; R7 = H, alkyl, halogen, OH, alkoxy] were prepared for use as inhibitors of one or two of the isoforms of Akt, a serine/threonine protein kinase, acting particularly on the pleckstrin homol. domain of Akt. Thus, 3,6-dichloropyridazine was converted to its 4-cyclobutyl derivative which was cyclized with BzNHNH2 and aminated to give I [R1 = Ph, R2 = NHCH2CMe2CH2NMe2, R3 = H, R4 = cyclobutyl]. This compound had IC50 for inhibition of Akt1 of 1.4 μM.


IT 612847-30-OP 612847-32-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)

RN 612847-30-0 CAPLUS
 CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
 CRN 612847-29-7
 CMF C34 H29 N5 O3




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 612847-32-2 CAPLUS
 CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:816232 CAPLUS
 DOCUMENT NUMBER: 139:323527
 TITLE: Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer
 INVENTOR(S): Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber, Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman, George D.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 170 pp.
 CODEN: PIXXD3
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084473	A2	20031016	WO 2003-US10632	20030404
WO 2003084473	A3	20040212		
M: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003226301	A1	20031020	AU 2003-226301	20030404
US 2006142178	A1	20060629	US 2004-510068	20041004
PRIORITY APPLN. INFO.:				
				US 2002-370827P
				US 2002-417202P
				US 2002-417202P
				WO 2003-US10632
				W 20030404

GI

CM 1
 CRN 612847-31-1
 CMF C34 H29 N5 O3



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




IT 612847-28-6P 612847-34-4P 612847-36-6P
 612847-38-8P 612847-41-3P 612847-42-4P
 612847-43-5P 612847-45-7P 612847-47-9P
 612847-49-1P 612847-51-5P 612847-53-7P
 612847-55-9P 612847-57-1P 612847-59-3P
 612847-61-7P 612847-63-9P 612847-65-1P
 612847-67-3P 612847-69-5P 612847-71-7P
 612847-73-9P 612847-75-1P 612847-77-3P
 612847-79-5P 612847-81-7P 612847-83-9P
 612847-85-1P 612847-87-3P 612847-89-5P
 612847-91-7P 612847-93-9P 612847-95-1P
 612847-97-3P 612847-99-5P 612848-01-7P
 612848-03-9P 612848-05-1P 612848-07-3P
 612848-09-5P 612848-11-7P 612848-13-9P
 612848-15-1P 612848-17-3P 612848-19-5P
 612848-21-7P 612848-23-9P 612848-25-1P
 612848-27-3P 612848-29-5P 612848-31-7P
 612848-33-9P 612848-35-1P 612848-37-3P
 612848-39-5P 612848-41-7P 612848-43-9P
 612848-45-1P 612848-47-3P 612848-49-5P
 612848-51-7P 612848-53-9P 612848-55-1P
 612848-57-3P 612848-59-5P 612848-61-7P
 612848-63-9P 612848-65-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)


RN 612847-28-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
 CRN 612847-27-5
 CMF C33 H29 N5 O



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-34-4 CAPLUS


CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-33-3
CMP C40 H38 N8 O2




PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-36-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-35-5
CMP C32 H28 N6 O



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-38-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(2-phenylpyrido[3,4-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-37-7
CMP C32 H28 N6 O



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-41-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-40-2
CMP C34 H29 N9 O




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-42-4 CAPLUS

CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 612847-43-5 CAPLUS

CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 612847-45-7 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-(6,7-diamino-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-44-6
CMP C33 H31 N7 O



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-47-9 CAPLUS

CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-46-8
CMP C33 H28 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-49-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(3-(2-aminophenyl)-2-quinoxalinyloxy)methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-48-0
CMF C33 H30 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-51-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-50-4
CMF C32 H26 Cl2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-53-7 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-52-6
CMF C33 H27 N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-55-9 CAPLUS
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-54-8
CMF C33 H27 F3 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-57-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-56-0
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-59-3 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-58-2
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612847-61-7 CAPLUS
CN Benzamide, 3,5-difluoro-N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl)-], trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-60-6
CMP C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-63-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl)-], trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-62-8
CMP C29 H25 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-65-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl)-], trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-64-0
CMP C29 H25 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-67-3 CAPLUS
CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[(4-(3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl)-], trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-66-2
CMP C29 H29 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-85-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[(4-(7-amino-3-phenyl-2-quinoxalinyloxy)methyl]-3-pyrrolidinyl)-], trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-84-4
CMP C29 H26 N6 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-87-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl)methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 612847-86-6
CMP C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612847-89-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl)methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-88-8
CMP C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-91-3 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-((4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl)methyl)-3-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-90-2
CMP C28 H24 N6 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-93-5 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-((4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl)methyl)-3-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-92-4
CMP C28 H24 N6 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612847-95-7 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-((4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl)methyl)-3-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1
CRN 612847-94-6
CMP C28 H24 N6 O S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMP C2 H F3 O2




RN 612847-97-9 CAPLUS
CN 5-Thiazolecarboxamide, N-((3R)-1-((4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl)methyl)-3-pyrrolidinyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 612847-96-8
CMP C29 H25 N5 O2 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612847-99-1 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[1-((4-(3-phenyl-2-quinoxaliny)phenyl)methyl)-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612847-98-0
CMP C32 H29 N5 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-01-8 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[1-((4-(3-phenyl-2-quinoxaliny)phenyl)methyl)-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-00-7
CMP C32 H29 N5 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-03-0 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[1-((4-(3-phenyl-2-quinoxaliny)phenyl)methyl)-3-azetidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

INDEX NAME)

CM 1
CRN 612848-02-9
CMP C32 H29 N5 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-05-2 CAPLUS
CN Benzoic acid, 3-[[[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyloxy]carbonyl]amino]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-04-1
CMP C33 H29 N5 O3




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612848-07-4 CAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-azetidinyloxy]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-06-3
CMP C32 H27 F2 N5 O2



CM 2


CRN 76-05-1
CMP C2 H F3 O2




RN 612848-09-6 CAPLUS
CN 5-Quinoxalinol, 2-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-08-5
CMP C34 H31 N5 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612848-11-0 CAPLUS
CN Acetamide, N-[2-[[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxalinyloxy]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-10-9
CMP C37 H37 N7 O2



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-13-2 CAPLUS
CN Acetamide, N-[3-[[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxalinyloxy]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-12-1
CMP C37 H37 N7 O2



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 612848-15-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-14-3
CMP C31 H28 N8



CM 2


CRN 76-05-1
CMP C2 H F3 O2




RN 612848-17-6 CAPLUS
CN 6-Quinoxalinamine, 3-[[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-16-5
CMF C31 H29 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-19-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-18-7
CMF C31 H27 Cl N8




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-21-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-

piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-20-1
CMF C31 H29 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-23-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-chloro-3-phenyl-2-quinoxaliny)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-22-3
CMF C31 H27 Cl N8




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-25-6 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-24-5
CMF C30 H27 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-27-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-26-7
CMF C30 H27 N9




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612848-29-0 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-28-9
CMF C30 H27 N9




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612848-31-4 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 612848-30-3
CMF C31 H28 N8 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-33-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-32-5
CMP C32 H28 N8 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-35-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-34-7
CMP C32 H28 N8 O2




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-37-0 CAPLUS
CN Quinoxaline, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-36-9
CMP C32 H28 N6




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-39-2 CAPLUS

CN 6-Quinoxalinamine, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-38-1
CMP C32 H29 N7




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-41-6 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-40-5
CMP C32 H29 N7




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-43-8 CAPLUS
CN Pyrido[2,3-b]pyrazine, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-42-7
CMP C31 H27 N7




CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 612848-45-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinolinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 612848-44-9
CMP C34 H30 N4 O




CM 2
CRN 76-05-1
CMP C2 H F3 O2



RN 612848-47-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[4-[[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-46-1
CMF C34 H29 N9 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-49-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-48-3
CMF C32 H28 N12



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-51-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-50-7
CMF C32 H28 N12



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-53-0 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-7-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-52-9
CMF C31 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-55-2 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-6-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-54-1
CMF C31 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-56-3 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-43-5
CMF C40 H43 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612848-57-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-42-4
CMF C40 H43 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-59-6 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-


1-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl-6-quinoxaliny]carbonyl]amino]-
(2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-58-5
CMP C40 H40 N6 O7

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612848-61-0 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-2-phenyl-6-quinoxaliny]carbonyl]amino]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-60-9
CMP C40 H40 N6 O7


Absolute stereochemistry.

PAGE 1-B



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612848-65-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[7-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612848-64-3
CMP C41 H42 N6 O7

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 612848-63-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxaliny]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-62-1
CMP C41 H42 N6 O7


Absolute stereochemistry.

PAGE 1-A




CM 2

CRN 76-05-1
CMP C2 H F3 O2




IT 612848-75-6P 612848-76-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)

RN 612848-75-6 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 612848-76-7 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:41482 CAPLUS
DOCUMENT NUMBER: 116:41482
TITLE: Preparation of 5,8-dimethoxy-2,3-bis(4-aminomethylphenyl)quinoxalines as protozoacides
INVENTOR(S): Venugopalan, Bindumadhavan; Chatterjee, Deepak Kumar; De Souza, Noel John; Rupp, Richard Helmut
PATENT ASSIGNOR(S): Hoechst India Ltd., India
SOURCE: Indian, 17 pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 166761	A	19900714	IN 1987-BO125	19870410
PRIORITY APPLN. INFO.:			IN 1987-BO125	19870410

OTHER SOURCE(S): MARPAT 116:41482
GI




AB Title compds. [I; R = NR₁R₂; R₁, R₂ = H, (hydroxy)alkyl, alkenyl, (un)substituted acyl; NR₁R₂ = heterocyclyl] were prepared as protozoacides (no data). Thus, 2,3-dinitro-1,4-dimethoxybenzene was hydrogenated and the product cyclocondensed with [4-(BrH₂C)C₆H₄CO]₂ to give I (R = Br) which was condensed with piperidine to give I (R = piperidino).

IT 136270-42-3P 136270-43-4P 136270-45-6P
136270-48-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, as protozoacide)



RN 136270-42-3 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 136270-43-4 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-((4-phenyl-1-piperidinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)




AB Various derivs. of 2,3-bis(4-bromomethylphenyl)dimethoxyquinoxaline (I) and 2,3-bis(4-aminophenyl)dimethoxyquinoxaline (II) have been synthesized. Thus, I reacted with piperidine to give bis(piperidinomethylphenyl)quinoxaline III. II reacted with thiophosgene to give bis(isothiocyanatophenyl)quinoxaline IV. A few compds. display moderate antiamebic activity against Entamoeba histolytica in hepatic amebiasis in mice and in intestinal amebiasis in the weanling Wistar rat model.

IT 136270-42-3P 136270-43-4P 136270-44-5P
136270-45-6P 136270-46-7P 136270-47-8P
136270-48-9P 136293-53-3P 137389-47-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiamebic activity of)

RN 136270-42-3 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 136270-43-4 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-((4-phenyl-1-piperidinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)


RN 136270-45-6 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 136270-48-9 CAPLUS

CN Quinoxaline, 2,3-bis[4-((hexahydro-1H-azepin-1-yl)methyl)phenyl]-5,8-dimethoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:559095 CAPLUS

DOCUMENT NUMBER: 115:159095

TITLE: Synthesis and antiamebic activity of 2,3-diaryl-5,8-dimethoxyquinoxalines

AUTHOR(S): Venugopalan, B.; Sureshi, S.; Karnik, P. J.; De Souza, N. J.; Chatterjee, D. K.; Iyer, S. N.

CORPORATE SOURCE: Dep. Chem., Hoechst Indian Ltd., Bombay, 400 080, India


SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(8), 777-83

CODEN: IJSEDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

GI




RN 136270-44-5 CAPLUS

CN 4-Piperidinone, 1,1'-[(5,8-dimethoxy-2,3-quinoxalinediyl)bis(4,1-phenylenemethylene)]bis- (9CI) (CA INDEX NAME)




RN 136270-45-6 CAPLUS

CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 136270-46-7 CAPLUS


CN Quinoxaline, 2,3-bis[4-((1,4'-bipiperidin-1'-yl)methyl)phenyl]-5,8-dimethoxy- (9CI) (CA INDEX NAME)




RN 136270-47-8 CAPLUS
CN Quinoxaline, 2,3-bis[4-[(2,6-dimethyl-1-piperidinyl)methyl]phenyl]-5,8-dimethoxy- (9CI) (CA INDEX NAME)




RN 136270-48-9 CAPLUS
CN Quinoxaline, 2,3-bis[4-[(hexahydro-1H-azepin-1-yl)methyl]phenyl]-5,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 136293-53-3 CAPLUS
CN 5,8-Quinoxalinediol, 2,3-bis[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 137389-47-0 CAPLUS
CN Quinoxaline, 6,7-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



=> LOG HOLD
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:39:03 ON 02 NOV 2006

SINCE FILE ENTRY	TOTAL SESSION
38.20	205.35
SINCE FILE ENTRY	TOTAL SESSION
-4.50	-4.50